Scientists test new drug duo in fight against aggressive sarcomas
NCT ID NCT03123276
Summary
This study tested the safety of combining two drugs, pembrolizumab and gemcitabine, in patients with advanced forms of sarcoma called leiomyosarcoma and undifferentiated pleomorphic sarcoma. The main goal was to find the highest dose of gemcitabine that could be safely given with pembrolizumab. A total of 25 patients participated to help researchers understand the side effects and see early signs of whether the treatment might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Royal Marsden
London, United Kingdom
Conditions
Explore the condition pages connected to this study.